As the US healthcare system adjusts to the “new” norm brought on by the COVID-19 pandemic, the US Orthobiologics market rallied in Q320, ending the quarter up +2.3% YoY.Among the many topics, including company revenues, shares, charts and expert analysis, covered in the comprehensive Q320 Orthobio Market Recap* are:
- Complete Q320 Orthobiologics Market Highlights
- Key Factors Fueling Positive Growth
- Dynamics Impeding Growth
- Trends Impacting Near-term Growth
- Q320 Regulatory Highlights
During Q320, elective surgeries commenced and revenues neared pre-COVID levels, with some companies rebounding with positive year-over-year growth. While surgeons worked through backlog cases and the medical community navigated through the pandemic, companies pivoted, adjusting near-term tactics and longer-term strategic imperatives to remain solvent or take advantage of the new norm. Several factors contributed to Q3 results and some are likely to shape the landscape going forward ...
*The entire article, including revenue, shares and links can only be viewed by SmartTRAK subscribers to this module. For more information on how to receive a demo and subscribe, please click the button below.
SmartTRAK is a comprehensive, easy-to-use, business intelligence solution that networks an entire organization with real-time market data and analysis. Used by the 15 top Advanced Wound Care companies and 8 of the 10 top Orthopedic companies, SmartTRAK transforms the delivery of healthcare business information into a cost-effective solution for life science corporations to increase proficiency, improve productivity and reduce cost.